Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007097 (carcinoma)
 152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A patient, male, 57 years old, with hepatoid adenocarcinoma of the stomach is reported. Chief complaint was right upper abdominal mass and anorexia for 11 months. The patient's serum AFP level was found to be elevated (652.8 ng/ml) and a mass was observed in left hepatic lobe by isotope scan. It was diagnosed as primary hepatic carcinoma. A large ulcerative tumor (14 x 13 x 0.8 cm) in gastric pylorus-antrum and liver metastasis were found by autopsy. Histologically, the tumor, diagnosed as hepatoid adenocarcinoma of the stomach by pathology, was composed of two but closely related to well differentiated tubular papillary adenocarcinoma and differentiated hepatoid adenocarcinoma. Histogenesis, production of AFP and its significance, and clinicopathologic characteristics of this tumor are discussed with review of literature.
 ...
PMID:[A case of hepatoid adenocarcinoma of the stomach]. 247 87

Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma. Forty-six patients received 5-fluorouracil as an intravenous injection on days 1-5 and recombinant human interferon-gamma as an intramuscular injection on days 1-14, followed by a rest period of 14 days; courses were repeated every 28 days. In the phase I study, cohorts of two patients received a stepwise dose level increase to achieve the maximum tolerated dose (MTD), at which a total of six patients were studied. The dose levels constituting the MTD were as follows: 5-fluorouracil (500 g/m2/day) and recombinant gamma-interferon (0.5 mg/m2/day). Four patients achieved a partial response in the phase I study. In the phase II study, 30 patients received therapy at the MTD. Among 29 evaluable patients in the phase II study, two patients achieved a partial response. Common toxicities included malaise, fever, anorexia, nausea and vomiting, and diarrhea. Transient severe myelosuppression was common but did not result in significant morbidity. Our data suggest that the combination of 5-fluorouracil and recombinant gamma-interferon did not have the same antitumor effect in patients as it had in the preclinical experiments.
 ...
PMID:Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. 249 63

Anorexia, dysphagia, and dysgeusia are the most prevalent symptoms in head and neck cancer patients during radiation therapy. The patients, who were in poor general condition, suffered marked loss of body weight and consequently were unable to tolerate further anti-cancer treatments. Aggressive nutritional support to the head and neck cancer patients was started in April, 1986 to improve the general condition of these patients in our hospital. The physiological condition of 152 patients who underwent nutritional support were evaluated as a study group (Group I) between August 1986 and May 1987. Group II, 165 patients without nutritional care were evaluated as a control group between August 1985 and May 1986. In Group I, oral supplementary diets or enteral feedings were provided as nutritional support to all of the anorectic patients. Anthropometric measurement and laboratory data were collected in both groups at the several time points. An average of 1.1 kilogram (Kg) and 3.5Kg body weight loss was observed in Group I and Group II, respectively (P less than 0.005). In patients diagnosed with nasopharyngeal carcinoma, the average duration of radiation treatment was 11 days shorter in Group I than that in Group II (42 vs 53 days). In conclusion, aggressive nutritional care performed by a group of clinical staff, which included doctors (radiation oncologist), dietitians and oncologic nurses, was sufficient to improve the general condition of the head and neck cancer patients during radiation therapy and to therefore increase the recovery rate of these patients after radiation treatments.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Clinical evaluation of aggressive nutritional care to head and neck cancer patients during radiation therapy]. 250 13

In Wistar rats bearing a Walker-256 carcinoma flank tumor, a standard skin wound was inflicted on the backs of the animals. Nitrogen intake and nitrogen balance measures were obtained. The standard wound did not promote tumor growth. Wound contraction in tumor-bearing animals was not different from that in tumor-free animals. Tumor-bearing rats had anorexia, lower nitrogen intake and a tendency to lower their nitrogen balance. These findings suggest that both cancer and wound healing are privileged metabolic events, having as a consequence sacrifice of the host.
 ...
PMID:An experimental study of the impact of cancer on nitrogen metabolism and wound healing. 252 Mar 37

Fifteen patients (six patients with adenocarcinoma, seven patients with squamous cell carcinoma, and two patients with large cell carcinoma) with advanced non-small cell lung cancer (NSCLC) were evaluable for mitomycin C (MMC; 8 mg/m2 day 1, 8, every 3-4 weeks) plus cisplatin (CDDP; 80 mg/m2 day 1, every 3-4 weeks). Ten patients had had prior chemotherapy. Among 15 evaluable patients, no patient achieved complete response, and two patients showed partial response. The response rate of MMC plus CDDP against NSCLC was 13.3%. Toxic effects included anorexia (80%), nausea and vomiting (67%), leukopenia (53%), anemia (47%), nephrotoxicity (47%), thrombopenia (27%), liver injury (27%), and fever (7%). These toxic effects were reversible and manageable. The combination of MMC and CDDP appears to be valuable regimen against advanced NSCLC.
 ...
PMID:[Pilot combination phase II study of mitomycin C plus cisplatin for non-small cell lung cancer]. 255 71

Three hundred five patients with advanced pancreatic and gastric carcinoma were randomly assigned to treatment with fluorouracil, fluorouracil plus doxorubicin (Adriamycin) (FA), or fluorouracil plus doxorubicin plus mitomycin (mitomycin C) (FAM). All regimens were equivalent with regard to patient survival. There is no reasonable likelihood that either the FA or FAM regimen could produce a meaningful survival advantage over fluorouracil alone. Interval to disease progression, objective response rates, and palliative effects (improved performance, body weight, or symptoms) were essentially equivalent among the three regimens. With regard to toxicity, the FAM regimen produced more anorexia, nausea, vomiting, leukopenia, thrombocytopenia, and cumulative bone marrow suppression. Fluorouracil alone produced more stomatitis and diarrhea. Because of a failure to produce improved survival or palliation, unrewarded toxicity, and excessive cost, neither the FA nor FAM regimen can be recommended for the treatment of advanced pancreatic or gastric cancer.
 ...
PMID:A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. 257 57

A phase II study of Vindesine for esophageal carcinoma was carried out cooperatively by 10 Japanese institutions. Fifty patients were enrolled in the study over a year and ten months. Four patients could not be evaluated because less than 4 weeks had elapsed since their preceding therapy. There were one complete remission and five partial remissions among the 46 remaining patients, a response rate of 13.0%. The patient experiencing the complete remission is still alive more than 24 months after treatment. The main side effects were depilation, anorexia, stomatitis and leukopenia. Thrombocytopenia and elevations of blood urea nitrogen and creatinine were not marked. There was no mortality connected with the administration of Vindesine. It was concluded that Vindesine is useful in the treatment of esophageal carcinoma as a single agent.
 ...
PMID:A phase II study of vindesine in the treatment of esophageal carcinoma. Japanese Esophageal Oncology Group. 260 39

Thirty-one patients with metastatic breast carcinoma refractory to standard hormonal and chemotherapy were treated with cisplatin 100 mg/m2 per course and etoposide 300 mg/m2 per course divided over 5 days. Courses were repeated at 3-6-week intervals, depending on the speed of recovery from myelosuppression. Of 29 evaluable patients, three had complete responses, eight had partial responses, eight had stable disease, and 10 had progressive disease. Nausea, emesis, anorexia, weakness, and easy fatigability were common but tolerable side effects. Myelosuppression was frequent and occasionally profound but there were no deaths from hemorrhage or infection. No significant renal toxicity was encountered. The combination of cisplatin and etoposide has sufficient antitumor activity with acceptable toxicity in heavily pretreated patients to justify its further study in breast cancer.
 ...
PMID:Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. 264 95

An 11-yr-old female beaver (Castor canadensis) died after a 3 1/2 mo course of intermittent diarrhea, lethargy and anorexia. A postmortem examination revealed both a necrotizing ulcerative colitis and bilaterally enlarged thyroid glands. Histologically, the necrotizing colitis was similar to that caused by canine or feline parvovirus. Thyroid glands were multilobulated. Lobules were composed of irregularly arranged, variably sized follicles, some of which contained colloid. Follicles were lined by a pleomorphic population of tall cuboidal to columnar epithelial cells. Capsular invasion was present. Similar cells, forming follicles were present within the pulmonary parenchyma. This is the first documented case of a thyroid follicular carcinoma with pulmonary metastases in a beaver.
 ...
PMID:Thyroid follicular carcinoma with pulmonary metastases in a beaver (Castor canadensis). 281 May 61

A 72 year-old man visited our hospital complaining of anorexia and hungry epigastric pain. Gastroscopy and upper G-I series examination established the diagnosis of double gastric cancers. Total gastrectomy, R2 lymphadenectomy and beta anastomosis were performed. The type IIc early cancer lesion at the pyloric vestibule was sm in depth and revealed a histological pattern of tubular adenocarcinoma. The multiple lesions on the anterior and posterior walls of the lesser curvature were a cluster of submucosal cysts, and were partially accompanied by signet-ring cell carcinoma having the depth m. The two lesions were histologically isolated without continuity, and the histology progress was PoHoeta (-) ps(-), Stage I, aw(-), ow(-). Postoperative course was uneventful. Though multiple diffuse ectopic gastric mucosa is seemed to be benign submucosal tumor of the stomach, occasional co-existence of cancer has been frequently reported. Even if the results of gastroscopy and upper G-I series results are negative, there is always a possible risk of overlooking a small cancerous focus. On detecting ectopic gastric mucosa, immediate and thorough resection seems desirable, especially when accompanied by cancer. The pathogenesis of multiple diffuse ectopic gastric mucosa has remained controversial and has been explained by the theory of either congenital or acquired aberration. From the histological findings, the pathogenesis of this case could not be determined.
 ...
PMID:[Early gastric cancer associated with ectopic gastric mucosa (submucosal cysts)]. 282 87


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>